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CONCLUSIONS: Recent updates on burden of disease estimates were used and
utilities included but due to the absence of trial data still a number of assumptions
were used. The outcomes of this modeling exercise show that a vaccine against
RSV might be cost-effective, but trial data are warranted.
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OBJECTIVES:To compare cost-effectiveness of tenofovir and other AN in treatment
of adults with CHB in Poland. METHODS: Analysis was performed from the public
payer perspective. A lifetime Marcov model (3-month cycle) was developed defin-
ing heath states based on HBV_DNA level. Following events were included: com-
plications (liver cirrhosis, hepatocellular carcinoma), drug resistance and relapse
after remission. Analysis was performed in total population (regardless of the
HBeAg status) and in subpopulation of HBeAg() patients. Analysis for HBeAg(-)
patients was impossible to conduct due to lack of effectiveness data. Effectiveness
parameters were based on MTC conducted in systematic review of randomized
clinical trials. In the analysis following costs were included: antiviral drugs, mon-
itoring, hospitalization and CHB complications treatment. The reliability of the
estimates was examined by sensitivity analyses of model parameters. RESULTS: In
total population the estimated lifetime QALY per patient were: 12.33 for tenofovir,
11.32 for entecavir and 11.64 for adefovir. The estimated differences in QALYs
between tenofovir and comparators were: 1.00 in comparison to entecavir and 0.69
in comparison to adefovir. The differences were not statistically significant. Aver-
age lifetime costs per patient were: 223,519 PLN for tenofovir, 358,565 PLN for en-
tecavir and 349,535 PLN for adefovir. The resulting difference in costs between
tenofovir and comparators were: -135,045 PLN in comparison to entecavir and
-126,016 PLN in comparison to adefovir. The results for HBeAg() subpopulation
were close to results for total population. CONCLUSIONS: Both in total population,
as well as in HBeAg() subpopulation, tenofovir dominates adefovir and entecavir,
which means that it allows for greater health effects (QALY, LYG) with lower costs
of treatment. Results of probabilistic sensitivity analysis indicates that tenofovir
therapy is cost-effective (for the assumed threshold of three GDP: 102,045 PLN) with
a probability of ca 82% when compared with adefovir and ca 86% in comparison to
entecavir.
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OBJECTIVES: In 2011, intranasal administrated live-attenuated influenza vaccine
(LAIV) for prophylaxis of seasonal influenza was approved in the EU for children
aged 2-17 years. Our objective was to estimate the potential epidemiological impact
and cost-effectiveness of the current policy to vaccinate people over 60 years and
people with underlying chronic conditions with trivalent inactivated vaccine (TIV)
compared to the addition of routine childhood vaccination with LAIV in Germany.
METHODS: A compartmental susceptible-exposed-infectious-recovered-suscepti-
ble (SEIRS) model populated with German specific data was developed to explore
the impact of vaccination on the transmission dynamics of seasonal influenza. In
addition, a decision tree was constructed to incorporate several consequences of
influenza infections and to compare costs and outcomes of different vaccination
strategies in the German health care setting. The time horizon was set to ten years
after the introduction of LAIV, assuming childhood vaccination coverage of 70%.
Input data were based on published literature or were derived by expert consulting
using the Delphi technique. RESULTS: Under base-case assumptions, annual rou-
tine vaccination of children would prevent 8.8 million influenza illnesses, resulting
in a reduction of 273,124 cases of acute otitis media and 68,102 cases of community-
acquired pneumonia over ten years if left undiscounted. The discounted incremen-
tal cost-effectiveness ratio was €9601 per QALY gained from a third-party payer
perspective, when compared to the current strategy of vaccinating only risk groups
with TIV. Inclusion of patient co-payments and indirect costs resulted in a dis-
counted 10-year cost-saving to society of €1.16 billion. CONCLUSIONS: Compared
with the current vaccination policy, introducing childhood and adolescent vacci-
nation with LAIV can substantially increase benefits and reduce overall costs when
adopting a societal perspective. Using the commonly cited threshold of €50,000 per
QALY gained, routine vaccination of children with LAIV can be considered cost-
effective from a third-party payer perspective.
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OBJECTIVES: This study aims to evaluate the cost-effectiveness of peg-interferon
alpha-2a plus ribavirin compared with conventional interferon alpha-2a plus riba-
virin for the treatment of chronic hepatitis C (CHC) in China. METHODS: A Markov
health-state model was designed to estimate the direct medical costs and out-
comes (life year gained and quality adjusted life year, QALY) of treating CHC. The
model consists of 7 health states: cured (sustained virological response), CHC, com-
pensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma, liver
transplant, and death. Based on literature research, a two-round expert panel sur-
vey was conducted among experienced clinicians nationally in China to identify
medical cost and clinical efficacy data. The evaluation was conducted from a per-
spective of China’s health insurance system to compare combination therapy sce-
narios of peg-interferon alfa-2a (40KD) plus ribavirin with conventional interferon
alfa-2a plus ribavirin. The evolution of a cohort of CHC patients was simulated
along 40 years with yearly cycles. A discounting rate at 3% was used to discount
utilities and medical costs happened at different years. A univariate sensitivity
analysis was performed to understand the key drivers and general sensitivity of the
model. RESULTS: The model showed that peg-interferon alpha-2a scenario could
prolong 2.25 (30.02 years vs. 27.77 years) total life years compared with conven-
tional interferon alpha-2a scenario. The discounted QALYs generated by peg-inter-
feron were 2.19 longer than that of conventional interferon (18.58 QALYs vs. 16.39
QALYs). The discounted mean total cost per patient treated with peg-interferon
alpha-2a scenario was 114,751 CNY (US$17,930), and 130,047 CNY (US$20,320) for
patient treated with conventional interferon. CONCLUSIONS: The results of the
model suggest that peg-interferon alfa-2a treatment is dominant in both health
outcomes and long-term treatment costs compared with conventional interferon
alpha-2a for the treatment of CHC, which means peg-interferon alfa-2a treatment
can generate cost savings for the China’s health insurance system.
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OBJECTIVES: Atazanavir/r (ATV/r) and darunavir/r (DRV/r) are commonly used to
suppress HIV in Germany. Compared to lopinavir/r, both have demonstrated sim-
ilar relative efficacy in randomized clinical trials (RCT) in previously untreated
patients; whereas annual drug acquisition costs are 250 euro more for DRV/r. How-
ever, the objective was to estimate how these would translate into costs and ef-
fects, after 5 and 25 years. METHODS: The cost-effectiveness was forecasted using
a microsimulation-model (monthly cycles) for previously untreated HIV-patients
Response to medication was modeled as a reduction in HIV-RNA viral-load. In
accordance with literature, increase in CD4 could persist up to 5 years while
having a response; whereas no response resulted in the opposite. The occurrences
of AIDS defining events and non-AIDS defining malignancies were linked to the
current CD4 and independent of therapy. Adverse events (AE) on the other hand
were treatment-specific and the following were considered: 1) diarrhea; 2) dizzi-
ness; 3) jaundice; 4) nausea; and 5) rash. Toxicities associated with the long-term
use of agents considered in the model included: 1) cardiovascular events; 2) renal
insufficiency; and 3) hepatic failure. Drug efficacy and AE incidences were based on
published RCTs - compared via an indirect comparison - whereas, other data was
based on published literature. RESULTS: After 5 years, initiation with ATV/r use
was found to be associated with a lower total cost compared to DRV/r. In the
long-term (i.e. 25 year time horizon) the use of ATV/r was found to be associated
with an increase in survival of 16.0 (discounted) years; 0.31 life years and 0.55
QALYs compared to DRV/r. This resulted in an ICUR of € 11,241 per QALY gained.
Results were most sensitive to changes in virological parameters, market shares for
future lines and cost per CD4-level. CONCLUSIONS: The model forecasts ATV/r to
be cost-effective compared to DRV/r in Germany.
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OBJECTIVES: To assess cost-effectiveness of CMV disease prophylaxis prolonga-
tion in kidney transplant recipients from 110 to 200 days from Polish public payer’s
perspective. METHODS: Clinical efficacy and safety of prolonged to 200 days pro-
phylaxis of CMV disease in kidney transplant recipients (D/R-) was assessed in
systematic review. Following measurable differential direct medical costs were
estimated and included: costs of drugs and diagnostic, hospital/ambulatory proce-
dures, adverse events treatment, acute rejection, CMV disease treatment, oppor-
tunistic infections treatment, hemodialysis and subsequent kidney transplanta-
tion. Cost data were gathered in 4 medical centers. Markov model was used to
calculate costs and efficacy in 23.5 years time horizon - the maximum expected
survival of kidney transplant recipient. Costs and clinical effects were discounted
(5% for costs and effects, 0% for costs and effects, 5% for costs and 0% for effects).
Probabilistic, one-way, multiway sensitivity analyses were conducted. RESULTS:
The prolongation to 200 days of CMV disease prophylaxis in kidney transplant
recipients is lined to reduction in frequency of CMV infections, acute transplant
rejections, loss of graft functions and need of subsequent kidney transplantation.
In the 23.5 years gain of 0.3846 life years and 0.3178 quality adjusted life years can
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be achieved. Total discounted costs in 23.5 years were 557 766.80 PLN (1EURO3.96
PLN) for patients subjected to 200 days prophylaxis and 542 509.92 PLN for patients
subjected to 110 days prophylaxis. The incremental cost-effectiveness ratio (ICER)
was 39,669 PLN and cost-utility ratio (ICUR) 48,008 PLN. Sensitivity analysis con-
firmed the base case analysis results. The results were sensitive only to the time
horizon assumed (when time horizon was shorter than 4 years ICER/ICUR were
above the accepted 110,000 PLN cost-effectiveness threshold). CONCLUSIONS: The
prolongation of CMV disease prophylaxis in kidney transplant recipients from 110
to 200 days is highly cost-effective from Polish payer perspective.
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OBJECTIVES: This study will evaluate lifetime cost-utility of a therapy based on
lopinavir/ritonavir vs atazanavir ritonavir, using a tenofovir-emtricitabine back-
bone, in an Italian cohort of HIV infected anti-retroviral-naïve patients. An inter-
national literature review revealed, that there are limited useful data to inform
Italian decision makers, taking into consideration Country specific costs and
utility. METHODS: Starting from the Broder (2011) Markov microsimulation model
and CASTLE study data, an Italian model was developed to specify direct costs and
health outcomes from Italian HIV-infected patients and their treatment, adopting
a national health service (NHS) payer perspective. The Health State (HS) transition
probabilities were assessed within a sample of 319 patients on treatment within
the Lombardy Region (the probability vector took into consideration the results of
the 96-week CASTLE trial, the principal published literature and the evidence re-
lated to the Italian population in terms of cholesterol changes, coronary heart
disease (CHD) events and adverse events (AEs). Costs related to AEs and to the care
of HIV patients were correlated to clinical effectiveness data, as well as institu-
tional indications, protocols and reimbursement tariff of hospitals located in Lom-
bardy Region. RESULTS: The newly developed Italian Markov model consisting of 8
HS, informs about the distribution of the Italian population, and forecasting the
evolution of the clinical pathway of anti-retroviral-naïve patients through different
stages up to death. Clinical effectiveness and absorption of resources were inves-
tigated to truly represent the Italian HIV context. CONCLUSIONS: The innovative
method of this Markov model construction based on national data, ensures the
opportunity of a closer results alignment to specific Italian costs, and to its usability
from an Italian decision making and payer’s perspective.
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OBJECTIVES: Every year 5-25% of the world’s population suffers from influenza.
Influenza and ILI (influenza like illness) among working adults are responsible for
the enhanced sickness absenteeism, limited work capacity and efficiency, as well
as for the increased health service demand. The aim of this pilot study was to
estimate the indirect cost of influenza and ILI (both absenteeism and presenteeism)
from emloper’s perspective. METHODS: Data was collected from Polish citizens in
working age, who were employed at the time of collecting data. Human Capital
Approach method was used in quantifying costs. Modified version of Work Produc-
tivity and Activity Impairment General Health questionnaire was used to estimate
absenteeism and presenteeism in the population. Responders were questioned
about the period from the first day of January 2011 to the day of the questionnaire
completion, which represents the period when the highest ILI incidence rate. The
results of the questionnaire were extrapolated for the whole year of 2011. The
indirect costs were calculated on the basis of the average gross wage value in the
corporate sector in 2011, which amounts to 911 EUR (1 EUR3.95 PLN). RESULTS:
The final population comprised 134 employees (average age 31 years, 56.7% men).
Immunized against influenza were 23.1% of the people who participated in the
study. 53.7% of all respondents reported that during the investigation period had
influenza or influenza-like symptoms. The productivity loss at workplace due to
illness was estimated at 4.0% (3,2 vs. 4,2, Immunized vs. non-immunized, respec-
tivetly; p0,44). Estimated absenteeism equaled 2.2% (1,7 vs 2,4, Immunized vs
non-immunized, respectively; p0,88).CONCLUSIONS: Indirect costs of productiv-
ity loss due to influenza and ILI are substantial to Polish economy. Due to the
relatively small non-representative population results should be treated with cau-
tion.
Infection – Patient-Reported Outcomes & Preference-Based Studies
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OBJECTIVES: To assess adherence to treatment for HCV monoinfected and HCV/
HIV co-infected patients, interim analysis at 12 weeks after therapy initiation.
METHODS: Observational, prospective study performed by 120 investigators in
Spain. Patients were hepatitis C (HCV) monoinfected or HCV/HIV co-infected, 18
years and naïve to HCV treatment. Visits were at treatment initiation (baseline), 4,
12, and every 24 weeks during HCV therapy and 24 weeks after finalization; only
interim results up to wk12 are presented. Each visit assessed adherence by Ad-
hepta and Morinsky-Green questionnaires. Adhepta questionnaire includes two
questions related to treatment adherence and 11 (monoinfected) or 13 (co-infected)
questions about reasons for non-adherence; non-adherence to treatment was as-
sessed following the 80/80/80 rule (not administered any HCV drug on 20% of the
occasions). RESULTS: Evaluable patients were 1,120, 801 monoinfected (68.3%
male) and 319 co-infected (74.9% male). Mean (SD) age was 45.3 (8.8) years. Non-
adherent patients by Adhepta were 2.5% and 3.5% for monoinfected at wk4 and
wk12, respectively; and 2.7% and 2.5% patients, among co-infected. No differences
between study groups were observed. Non-adherent patients by Morisky-Green
were 14.0% and 14.8% at wk4, and wk12, respectively for monoinfected; and 23.3%
and 23.2% for co-infected. Monoinfected patients were more adherent to treatment
than co-infected patients at wk4 and wk12 (p0.05). Assessed by Adhepta ques-
tionnaire, non-adherence most common reason reported was ‘forgetting to take
the drug’ (8.2% monoinfected and 10.8% co-infected).CONCLUSIONS:Adherence to
treatment remains constant through 12 weeks after treatment initiation. Differ-
ences in treatment adherence observed between both questionnaires must be
compared at the end of the HCV treatment and analysing their correlation with
patient self-reported medication record.
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OBJECTIVES:Determine real-life treatment continuation rates of chronic Hepatitis
C (HCV) treatment from a database of medicine dispensation in the Brazilian public
healthcare system. METHODS: Monthly data from a public database of medicine
dispensation was analyzed for a period of 17 months. The patient cohort was
defined as all new HCV (CID10 B18.2) patients initiating treatment between January
and December 2009. To identify HCV genotype 1 (G1) patients, it was assumed G1
patients initiated treatment with the pegylated forms of the interferons (pegIFN),
as defined by the Brazillian national guidelines for HCV. RESULTS: Between Janu-
ary and December 2009, 10,992 patients began treatment for HCV. Around 58% of
these patients were male with a median age of 49.7 years. Of these, 82% of patients
(9,019) were considered G1 as they began treatment with pegIFN and/or ribavirin.
Almost all patients (97%) began treatment with the treatment combination pegIFN
and ribavirin, with an equal split among both brands of pegIFN. For all HCV patients
treatment mean/median was 38,3/40 weeks compared to 40.2/44.0 weeks for G1
patients. At week 48, 63% of all HCV patients had discontinued treatment com-
pared to 58% of G1 patients. At week 24, around 19% of all HCV patients had
discontinued treatment compared to 18% of G1 patients. The maximum observed
treatment duration was 85 weeks in both all HCV and G1 patients. CONCLUSIONS:
Discontinuation rates before week 24 were similar between all HCV and G1 pa-
tients. Although 48 weeks of treatment is the established duration for G1 patients,
the majority of patients discontinue treatment earlier. These data, however, do not
guarantee patients actually receive treatment, as it follows medicine dispensation.
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OBJECTIVES: Immunization dose was considered as a late immunization dose if it
was administered after the recommended age. The aims of this study are to deter-
mine the frequency and percent of this type of doses among child immunization
schedule, and to determine the number of late immunization dose received by
each child.METHODS:Data was collected retrospectively from 528 children immu-
nization cards in Iraq to obtain the immunization history of each individual child.
This study was restricted the analyses to the vaccines administered before age 2
years. Each children must received seven doses at seven times, every dose consist
of many types of vaccines. RESULTS: More than 63% of late immunization doses
were shown in the third dose (OPVDTP) at fourth month of child life. Hundred and
forty five children were immunized with four late immunization doses out of seven
immunization doses, and 1.5% of children were immunized with 7 late immuniza-
tion doses. CONCLUSIONS: This study found that compliance with WHO immuni-
zation recommendations is low and inappropriate immunization doses were occur
frequently, and leading to incomplete or partial immunization compliance. With
an increase in parent’s knowledge of immunization guidelines against infectious
agents, it is very important to implement strategies that will lead to improved and
developed immunization practice and childhood immunization coverage in the
future.
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